Dianthus Therapeutics' Shares Surge 5.6% on Positive Investor Sentiment

Dianthus Therapeutics, Inc. (DNTH) shares rose 5.6% to close at $83.92, backed by solid volume. The stock has been surging due to positive investor expectations around its pipeline, including an early "GO" decision in the late-stage CAPTIVATE study for claseprubart in chronic inflammatory demyelinating polyneuropathy (CIDP). The FDA also agreed to proposed changes related to clinical development of claseprubart. The company is expected to post a quarterly loss of $1.17 per share, down 42.7% YoY, and revenues of $0.55 million, down 53% YoY.